A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population

The presence of germline and somatic deleterious mutations in the BRCA1 and BRCA2 genes has important clinical consequences for breast cancer (BC) patients. Analysis of the mutational status in BRCA genes is not yet common in public Latin American institutions; thus, our objective was to implement high-performance technology with highly reliable results with the possibility of analyzing several patients simultaneously, therefore reducing cost and work time. A prospective cohort of 252 unrelated sporadic breast cancer patients from the Mexican-mestizo population were analyzed using next generation sequencing (NGS) based on ion semiconductor sequencing. We found 28 pathogenic mutations (25 in BRCA1 and 13 in BRCA2), 11 of which had not been reported previously in Hispanic or Latin American populations. A total of 38 patients were positive for a pathogenic mutation representing 15% of our Mexican women cohort with breast cancer; 25 for BRCA1; and 13 for BRCA2. Our results revealed that there are mutations not analyzed by mutations panels, and our findings support the suitability of massive sequencing approaches in the public institutions of developing countries. Hence, BRCA screening should be offered to patients with breast cancer regardless of their family history of cancer in order to identify unaffected family carriers.

• Publication year

  2019

• Venue

  Cancers

• Publication date

  2019-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/cancers11091246PMID 31454914PMCID 6769960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population and breast cancer patients’ analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population

  2019influential reference
• Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms

  2019cited by this paper
• Triple negative breast cancer in Asia: An insider's view.

  2018cited by this paper
• Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing

  2017cited by this paper
• BRCA1/2 germline missense mutations: a systematic review

  2017cited by this paper
• The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing

  2017cited by this paper
• Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil

  2016cited by this paper
• An overview of triple-negative breast cancer

  2016cited by this paper
• Effect of BRCA germline mutations on breast cancer prognosis

  2016cited by this paper
• Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.

  2016cited by this paper
• Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis

  2016cited by this paper
• Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

  2015cited by this paper
• Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico

  2015cited by this paper
• BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review

  2015cited by this paper
• Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early‐onset breast/ovarian cancer from Tunisia

  2015cited by this paper
• The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer

  2015cited by this paper
• Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer

  2014cited by this paper
• Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients

  2014cited by this paper
• Prevalence and impact of founder mutations in hereditary breast cancer in Latin America

  2013cited by this paper
• Breast cancer in young women in Latin America: an unmet, growing burden.

  2013cited by this paper
• Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

  2013cited by this paper
• Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)

  2013cited by this paper
• Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil

  2013cited by this paper
• Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence

  2013influential reference
• Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer

  2012cited by this paper
• BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.

  2012cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families

  2011cited by this paper
• Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome

  2011cited by this paper
• Triple‐negative breast cancer in Hispanic patients

  2011influential reference
• Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population

  2011cited by this paper
• Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

  2010cited by this paper
• Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population

  2010cited by this paper
• Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin

  2009cited by this paper
• Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.

  2009cited by this paper
• Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba

  2008cited by this paper
• Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families

  2005cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• BRCA1 and BRCA2 mutation analysis of early‐onset and familial breast cancer cases in Mexico

  2002cited by this paper
• A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes

  2002cited by this paper
• Paternal contribution to the risk for pre-eclampsia.

  2002cited by this paper
• Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain

  2002cited by this paper
• Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing

  2002cited by this paper
• Risk factors of breast cancer in Mexican women.

  2000cited by this paper

• Spectrum of BRCA1/2 Pathogenic Variants in Southern and Western Asia-A Systematic Review.

  2025cites this paper
• Identification and Computational Analysis of BRCA2 Variants in Mexican Women from Jalisco, Mexico, with Breast and Ovarian Cancer

  2025cites this paper
• Clinical Management in BRCA Carriers with Early Breast Cancer

  2025cites this paper
• Pathogenic variants in BRCA1 and BRCA2 genes associated with female breast and ovarian cancer in the Mexican population

  2025influential citation
• Germline Genetic Variants in Cancer Predisposition Genes in Patients From Latin America and the Caribbean.

  2025cites this paper
• BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients

  2024cites this paper
• Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population

  2023cites this paper
• BRCA1/2 variants and copy number alterations status in non familial triple negative breast cancer and high grade serous ovarian cancer

  2022cites this paper
• Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania

  2022cites this paper
• Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients

  2022cites this paper
• Familial Genetic Cancer Risk Assessment with respect to a Silent BRCA2 mutation

  2021cites this paper
• Performance evaluation of an amplicon‐based next‐generation sequencing panel for BRCA1 and BRCA2 variant detection

  2020cites this paper
• Clinically Relevant Germline Mutations in a Cohort of Young Women with Breast Cancer: A Comprehensive Analysis of Hereditary-Cancer Genes from Whole-Exome Sequencing

  2020cites this paper
• Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer

  2020cites this paper
• Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.

  2020cites this paper